6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
drug O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Arterial B-OSE_Labeled_AE
Thromboembolic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

* O
Gastrointestinal B-OSE_Labeled_AE
Perforation I-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Impaired B-OSE_Labeled_AE
Wound I-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

* O
Patients O
with O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
B I-Not_AE_Candidate
or O
C O
Cirrhosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

* O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

* O
Proteinuria B-OSE_Labeled_AE
Including O
Nephrotic B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
. O

* O
Thyroid B-OSE_Labeled_AE
Dysfunction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

* O
The O
most O
common O
adverse O
reactions O
observed O
in O
single-agent O
CYRAMZA-treated O
patients O
at O
a O
rate O
of O
> O
=10 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
were O
hypertension B-OSE_Labeled_AE
and O
diarrhea B-OSE_Labeled_AE
. O

( O
6.1 O
) O
* O
The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
treated O
with O
CYRAMZA O
plus O
paclitaxel O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
paclitaxel O
were O
fatigue B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
epistaxis B-OSE_Labeled_AE
. O

( O
6.1 O
) O
* O
The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
treated O
with O
CYRAMZA O
plus O
docetaxel O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
docetaxel O
were O
neutropenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
/ O
asthenia B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
/ O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

( O
6.1 O
) O
* O
The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
FOLFIRI O
were O
diarrhea B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
. O

( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Eli O
Lilly O
and O
Company O
at O
1-800-LillyRx O
( O
1-800-545-5979 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Gastric O
Cancer O
Safety O
data O
are O
presented O
from O
two O
randomized O
, O
placebo O
controlled O
clinical O
trials O
in O
which O
patients O
received O
CYRAMZA O
: O
Study O
1 O
, O
a O
randomized O
( O
2:1 O
) O
, O
double-blind O
, O
clinical O
trial O
in O
which O
351 O
patients O
received O
either O
CYRAMZA O
8 O
mg/kg O
intravenously O
every O
two O
weeks O
or O
placebo O
every O
two O
weeks O
and O
Study O
2 O
, O
a O
double-blind O
, O
randomized O
( O
1:1 O
) O
clinical O
trial O
in O
which O
656 O
patients O
received O
paclitaxel O
80 O
mg/m O
2 O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
each O
28-day O
cycle O
plus O
either O
CYRAMZA O
8 O
mg/kg O
intravenously O
every O
two O
weeks O
or O
placebo O
every O
two O
weeks O
. O

Both O
trials O
excluded O
patients O
with O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
performance O
status O
( O
PS O
) O
of O
2 O
or O
greater O
, O
uncontrolled O
hypertension B-Not_AE_Candidate
, O
major O
surgery O
within O
28 O
days O
, O
or O
patients O
receiving O
chronic O
anti-platelet O
therapy O
other O
than O
once O
daily O
aspirin O
. O

Study O
1 O
excluded O
patients O
with O
bilirubin O
> O
=1.5 O
mg/dL O
and O
Study O
2 O
excluded O
patients O
with O
bilirubin O
> O
1.5 O
times O
the O
upper O
limit O
of O
normal O
. O

CYRAMZA O
Administered O
as O
a O
Single O
Agent O
Among O
236 O
patients O
who O
received O
CYRAMZA O
( O
safety O
population O
) O
in O
Study O
1 O
, O
median O
age O
was O
60 O
years O
, O
28 O
% O
were O
women O
, O
76 O
% O
were O
White O
, O
and O
16 O
% O
were O
Asian O
. O

Patients O
in O
Study O
1 O
received O
a O
median O
of O
4 O
doses O
of O
CYRAMZA O
; O
the O
median O
duration O
of O
exposure O
was O
8 O
weeks O
, O
and O
32 O
( O
14 O
% O
of O
236 O
) O
patients O
received O
CYRAMZA O
for O
at O
least O
six O
months O
. O

In O
Study O
1 O
, O
the O
most O
common O
adverse O
reactions O
( O
all O
grades O
) O
observed O
in O
CYRAMZA-treated O
patients O
at O
a O
rate O
of O
> O
=10 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
were O
hypertension B-OSE_Labeled_AE
and O
diarrhea B-OSE_Labeled_AE
. O

The O
most O
common O
serious O
adverse O
events O
with O
CYRAMZA O
were O
anemia B-OSE_Labeled_AE
( O
3.8 O
% O
) O
and O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
( O
2.1 O
% O
) O
. O

Red O
blood O
cell O
transfusions O
were O
given O
to O
11 O
% O
of O
CYRAMZA-treated O
patients O
versus O
8.7 O
% O
of O
patients O
who O
received O
placebo O
. O

Table O
2 O
provides O
the O
frequency O
and O
severity O
of O
adverse O
reactions O
in O
Study O
1 O
. O

Table O
2 O
: O
Adverse O
Reactions O
Occurring O
at O
Incidence O
Rate O
> O
=5 O
% O
and O
a O
> O
=2 O
% O
Difference O
Between O
Arms O
in O
Patients O
Receiving O
CYRAMZA O
in O
Study O
1 O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
CYRAMZA O
( O
8 O
mg/kg O
) O
N=236 O
Placebo O
N=115 O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
3-4 O
( O
Frequency O
% O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
3-4 O
( O
Frequency O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
14 O
1 O
9 O
2 O
Metabolism B-NonOSE_AE
and O
Nutrition O
Disorders I-NonOSE_AE
Hyponatremia B-OSE_Labeled_AE
6 O
3 O
2 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
9 O
0 O
3 O
0 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
16 O
8 O
8 O
3 O
Clinically O
relevant O
adverse O
reactions O
reported O
in O
> O
=1 O
% O
and O
< O
5 O
% O
of O
CYRAMZA-treated O
patients O
in O
Study O
1 O
were O
: O
neutropenia B-OSE_Labeled_AE
( O
4.7 O
% O
CYRAMZA O
versus O
0.9 O
% O
placebo O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
4.7 O
% O
CYRAMZA O
versus O
0.9 O
% O
placebo O
) O
, O
rash B-OSE_Labeled_AE
( O
4.2 O
% O
CYRAMZA O
versus O
1.7 O
% O
placebo O
) O
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
( O
2.1 O
% O
CYRAMZA O
versus O
0 O
% O
placebo O
) O
, O
and O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
1.7 O
% O
CYRAMZA O
versus O
0 O
% O
placebo O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
] O
. O

Across O
clinical O
trials O
of O
CYRAMZA O
administered O
as O
a O
single O
agent O
, O
clinically O
relevant O
adverse O
reactions O
( O
including O
Grade O
> O
=3 O
) O
reported O
in O
CYRAMZA-treated O
patients O
included O
proteinuria B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
and O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

In O
Study O
1 O
, O
according O
to O
laboratory O
assessment O
, O
8 O
% O
of O
CYRAMZA-treated O
patients O
developed O
proteinuria B-OSE_Labeled_AE
versus O
3 O
% O
of O
placebo-treated O
patients O
. O

Two O
patients O
discontinued O
CYRAMZA O
due O
to O
proteinuria B-OSE_Labeled_AE
. O

The O
rate O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
in O
Study O
1 O
was O
0.8 O
% O
and O
the O
rate O
of O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
0.4 O
% O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
, O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.4 O
, O
5.5 O
) O
] O
. O

CYRAMZA O
Administered O
in O
Combination O
with O
Paclitaxel O
Among O
327 O
patients O
who O
received O
CYRAMZA O
( O
safety O
population O
) O
in O
Study O
2 O
, O
median O
age O
was O
61 O
years O
, O
31 O
% O
were O
women O
, O
63 O
% O
were O
White O
, O
and O
33 O
% O
were O
Asian O
. O

Patients O
in O
Study O
2 O
received O
a O
median O
of O
9 O
doses O
of O
CYRAMZA O
; O
the O
median O
duration O
of O
exposure O
was O
18 O
weeks O
, O
and O
93 O
( O
28 O
% O
of O
327 O
) O
patients O
received O
CYRAMZA O
for O
at O
least O
six O
months O
. O

In O
Study O
2 O
, O
the O
most O
common O
adverse O
reactions O
( O
all O
grades O
) O
observed O
in O
patients O
treated O
with O
CYRAMZA O
plus O
paclitaxel O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
paclitaxel O
were O
fatigue B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
epistaxis B-OSE_Labeled_AE
. O

The O
most O
common O
serious O
adverse O
events O
with O
CYRAMZA O
plus O
paclitaxel O
were O
neutropenia B-OSE_Labeled_AE
( O
3.7 O
% O
) O
and O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
2.4 O
% O
) O
; O
19 O
% O
of O
patients O
treated O
with O
CYRAMZA O
plus O
paclitaxel O
received O
granulocyte O
colony-stimulating O
factors O
. O

Adverse O
reactions O
resulting O
in O
discontinuation O
of O
any O
component O
of O
the O
CYRAMZA O
plus O
paclitaxel O
combination O
in O
2 O
% O
or O
more O
patients O
in O
Study O
2 O
were O
neutropenia B-OSE_Labeled_AE
( O
4 O
% O
) O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
3 O
% O
) O
. O

Table O
3 O
provides O
the O
frequency O
and O
severity O
of O
adverse O
reactions O
in O
Study O
2 O
. O

Table O
3 O
: O
Adverse O
Reactions O
Occurring O
at O
Incidence O
Rate O
> O
=5 O
% O
and O
a O
> O
=2 O
% O
Difference O
Between O
Arms O
in O
Patients O
Receiving O
CYRAMZA O
plus O
Paclitaxel O
in O
Study O
2 O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
CYRAMZA O
plus O
Paclitaxel O
( O
N=327 O
) O
Placebo O
plus O
Paclitaxel O
( O
N=329 O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
> O
=3 O
( O
Frequency O
% O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
> O
=3 O
( O
Frequency O
% O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
54 O
41 O
31 O
19 O
Thrombocytopenia B-OSE_Labeled_AE
13 O
2 O
6 O
2 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
32 O
4 O
23 O
2 O
Gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
events O
10 O
4 O
6 O
2 O
Stomatitis B-OSE_Labeled_AE
20 O
1 O
7 O
1 O
General O
Disorders O
and O
Administration B-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
Asthenia B-OSE_Labeled_AE
57 O
12 O
44 O
6 O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
25 O
2 O
14 O
1 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypoalbuminemia B-OSE_Labeled_AE
11 O
1 O
5 O
1 O
Renal B-NonOSE_AE
and O
Urinary O
Disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
17 O
1 O
6 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
31 O
0 O
7 O
0 O
Vascular B-NonOSE_AE
Disorder I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
25 O
15 O
6 O
3 O
Clinically O
relevant O
adverse O
reactions O
reported O
in O
> O
=1 O
% O
and O
< O
5 O
% O
of O
the O
CYRAMZA O
plus O
paclitaxel O
treated O
patients O
in O
Study O
2 O
were O
sepsis B-OSE_Labeled_AE
( O
3.1 O
% O
CYRAMZA O
plus O
paclitaxel O
versus O
1.8 O
% O
placebo O
plus O
paclitaxel O
) O
and O
gastrointestinal B-OSE_Labeled_AE
perforations I-OSE_Labeled_AE
( O
1.2 O
% O
CYRAMZA O
plus O
paclitaxel O
versus O
0.3 O
% O
for O
placebo O
plus O
paclitaxel O
) O
. O

Non-Small O
Cell O
Lung O
Cancer O
CYRAMZA O
Administered O
in O
Combination O
with O
Docetaxel O
Study O
3 O
was O
a O
multinational O
, O
randomized O
, O
double-blind O
study O
conducted O
in O
patients O
with O
NSCLC B-Not_AE_Candidate
with O
disease O
progression O
on O
or O
after O
one O
platinum-based O
therapy O
for O
locally O
advanced O
or O
metastatic B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Patients O
received O
either O
CYRAMZA O
10 O
mg/kg O
intravenously O
plus O
docetaxel O
75 O
mg/m O
2 O
intravenously O
every O
3 O
weeks O
or O
placebo O
plus O
docetaxel O
75 O
mg/m O
2 O
intravenously O
every O
3 O
weeks O
. O

Due O
to O
an O
increased O
incidence O
of O
neutropenia B-OSE_Labeled_AE
and O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
in O
patients O
enrolled O
in O
East O
Asian O
sites O
, O
Study O
3 O
was O
amended O
and O
24 O
patients O
( O
11 O
CYRAMZA O
plus O
docetaxel O
, O
13 O
placebo O
plus O
docetaxel O
) O
at O
East O
Asian O
sites O
received O
a O
starting O
dose O
of O
docetaxel O
at O
60 O
mg/m O
2 O
every O
3 O
weeks O
. O

Study O
3 O
excluded O
patients O
with O
an O
ECOG O
PS O
of O
2 O
or O
greater O
, O
bilirubin O
greater O
than O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
, O
uncontrolled O
hypertension B-Not_AE_Candidate
, O
major O
surgery O
within O
28 O
days O
, O
radiographic O
evidence O
of O
major O
airway B-Not_AE_Candidate
or O
blood O
vessel O
invasion I-Not_AE_Candidate
by O
cancer O
, O
radiographic O
evidence O
of O
intra B-Not_AE_Candidate
- I-Not_AE_Candidate
tumor I-Not_AE_Candidate
cavitation I-Not_AE_Candidate
, O
or O
gross O
hemoptysis B-Not_AE_Candidate
within O
the O
preceding O
2 O
months O
, O
and O
patients O
receiving O
therapeutic O
anticoagulation O
or O
chronic O
anti-platelet O
therapy O
other O
than O
once O
daily O
aspirin O
. O

The O
study O
also O
excluded O
patients O
whose O
only O
prior O
treatment O
for O
advanced O
NSCLC B-Not_AE_Candidate
was O
a O
tyrosine O
kinase O
( O
epidermal O
growth O
factor O
receptor O
[ O
EGFR O
] O
or O
anaplastic O
lymphoma O
kinase O
[ O
ALK O
] O
) O
inhibitor O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
CYRAMZA O
plus O
docetaxel O
in O
627 O
patients O
in O
Study O
3 O
. O

Demographics O
and O
baseline O
characteristics O
were O
similar O
between O
treatment O
arms O
. O

Median O
age O
was O
62 O
years O
; O
67 O
% O
of O
patients O
were O
men O
; O
84 O
% O
were O
White O
and O
12 O
% O
were O
Asian O
; O
33 O
% O
had O
ECOG O
PS O
0 O
; O
74 O
% O
had O
non-squamous O
histology O
and O
25 O
% O
had O
squamous O
histology O
. O

Patients O
received O
a O
median O
of O
4.5 O
doses O
of O
CYRAMZA O
; O
the O
median O
duration O
of O
exposure O
was O
3.5 O
months O
, O
and O
195 O
( O
31 O
% O
of O
627 O
) O
patients O
received O
CYRAMZA O
for O
at O
least O
six O
months O
. O

In O
Study O
3 O
, O
the O
most O
common O
adverse O
reactions O
( O
all O
grades O
) O
observed O
in O
CYRAMZA O
plus O
docetaxel-treated O
patients O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
docetaxel O
were O
neutropenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
/ O
asthenia B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
/ O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

Treatment O
discontinuation O
due O
to O
adverse O
reactions O
occurred O
more O
frequently O
in O
CYRAMZA O
plus O
docetaxel-treated O
patients O
( O
9 O
% O
) O
than O
in O
placebo O
plus O
docetaxel-treated O
patients O
( O
5 O
% O
) O
. O

The O
most O
common O
adverse O
events O
leading O
to O
treatment O
discontinuation O
of O
CYRAMZA O
were O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
0.5 O
% O
) O
and O
epistaxis B-OSE_Labeled_AE
( O
0.3 O
% O
) O
. O

For O
patients O
with O
non-squamous O
histology O
, O
the O
overall O
incidence O
of O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
was O
7 O
% O
and O
the O
incidence O
of O
> O
=Grade O
3 O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
was O
1 O
% O
for O
CYRAMZA O
plus O
docetaxel O
compared O
to O
6 O
% O
overall O
incidence O
and O
1 O
% O
for O
> O
=Grade O
3 O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
for O
placebo O
plus O
docetaxel O
. O

For O
patients O
with O
squamous O
histology O
, O
the O
overall O
incidence O
of O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
was O
10 O
% O
and O
the O
incidence O
of O
> O
=Grade O
3 O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
was O
2 O
% O
for O
CYRAMZA O
plus O
docetaxel O
compared O
to O
12 O
% O
overall O
incidence O
and O
2 O
% O
for O
> O
=Grade O
3 O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
for O
placebo O
plus O
docetaxel O
. O

The O
most O
common O
serious O
adverse O
events O
with O
CYRAMZA O
plus O
docetaxel O
were O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
14 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
and O
neutropenia B-OSE_Labeled_AE
( O
5 O
% O
) O
. O

The O
use O
of O
granulocyte O
colony-stimulating O
factors O
was O
42 O
% O
in O
CYRAMZA O
plus O
docetaxel-treated O
patients O
versus O
37 O
% O
in O
patients O
who O
received O
placebo O
plus O
docetaxel O
. O

In O
patients O
> O
=65 O
years O
, O
there O
were O
18 O
( O
8 O
% O
) O
deaths B-NonOSE_AE
on O
treatment O
or O
within O
30 O
days O
of O
discontinuation O
for O
CYRAMZA O
plus O
docetaxel O
and O
9 O
( O
4 O
% O
) O
deaths B-NonOSE_AE
for O
placebo O
plus O
docetaxel O
. O

In O
patients O
< O
65 O
years O
, O
there O
were O
13 O
( O
3 O
% O
) O
deaths B-NonOSE_AE
on O
treatment O
or O
within O
30 O
days O
of O
discontinuation O
for O
CYRAMZA O
plus O
docetaxel O
and O
26 O
( O
6 O
% O
) O
deaths B-NonOSE_AE
for O
placebo O
plus O
docetaxel O
. O

Table O
4 O
provides O
the O
frequency O
and O
severity O
of O
adverse O
reactions O
in O
Study O
3 O
. O

Table O
4 O
: O
Adverse O
Reactions O
Occurring O
at O
Incidence O
Rate O
> O
=5 O
% O
and O
a O
> O
=2 O
% O
Difference O
Between O
Arms O
in O
Patients O
Receiving O
CYRAMZA O
in O
Study O
3 O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
CYRAMZA O
plus O
docetaxel O
( O
N=627 O
) O
Placebo O
plus O
docetaxel O
( O
N=618 O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
3-4 O
( O
Frequency O
% O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
3-4 O
( O
Frequency O
% O
) O
Blood B-NonOSE_AE
and O
Lymphatic O
System O
Disorders I-NonOSE_AE
Febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
16 O
16 O
10 O
10 O
Neutropenia B-OSE_Labeled_AE
55 O
49 O
46 O
40 O
Thrombocytopenia B-OSE_Labeled_AE
13 O
3 O
5 O
< O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
/ O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
37 O
7 O
19 O
2 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Lacrimation B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
13 O
< O
1 O
5 O
0 O
General O
Disorders O
and O
Administration B-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
Asthenia B-OSE_Labeled_AE
55 O
14 O
50 O
11 O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
16 O
0 O
9 O
< O
1 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
19 O
< O
1 O
7 O
< O
1 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
11 O
6 O
5 O
2 O
Clinically O
relevant O
adverse O
drug O
reactions O
reported O
in O
> O
=1 O
% O
and O
< O
5 O
% O
of O
the O
CYRAMZA O
plus O
docetaxel-treated O
patients O
in O
Study O
3 O
were O
hyponatremia B-OSE_Labeled_AE
( O
4.8 O
% O
CYRAMZA O
plus O
docetaxel O
versus O
2.4 O
% O
for O
placebo O
plus O
docetaxel O
) O
and O
proteinuria B-OSE_Labeled_AE
( O
3.3 O
% O
CYRAMZA O
plus O
docetaxel O
versus O
0.8 O
% O
placebo O
plus O
docetaxel O
) O
. O

Colorectal O
Cancer O
CYRAMZA O
Administered O
in O
Combination O
with O
FOLFIRI O
Study O
4 O
was O
a O
multinational O
, O
randomized O
, O
double-blind O
study O
conducted O
in O
patients O
with O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
with O
disease O
progression O
on O
or O
after O
therapy O
with O
bevacizumab O
, O
oxaliplatin O
, O
and O
a O
fluoropyrimidine O
. O

Patients O
received O
either O
CYRAMZA O
8 O
mg/kg O
intravenously O
plus O
FOLFIRI O
intravenously O
every O
2 O
weeks O
or O
placebo O
plus O
FOLFIRI O
intravenously O
every O
2 O
weeks O
. O

Study O
4 O
excluded O
patients O
with O
an O
ECOG O
PS O
of O
2 O
or O
greater O
, O
uncontrolled O
hypertension B-Not_AE_Candidate
, O
major O
surgery O
within O
28 O
days O
, O
and O
those O
who O
experienced O
any O
of O
the O
following O
during O
first-line O
therapy O
with O
a O
bevacizumab-containing O
regimen O
: O
an O
arterial B-Not_AE_Candidate
thrombotic I-Not_AE_Candidate
/thromboembolic O
event I-Not_AE_Candidate
; O
Grade O
4 O
hypertension B-Not_AE_Candidate
; O
Grade O
3 O
proteinuria B-Not_AE_Candidate
; O
a O
Grade O
3-4 O
bleeding B-Not_AE_Candidate
event O
; O
or O
bowel B-Not_AE_Candidate
perforation I-Not_AE_Candidate
. O

Demographics O
and O
baseline O
characteristics O
for O
the O
treated O
population O
were O
similar O
between O
treatment O
arms O
( O
n=1057 O
) O
. O

Median O
age O
was O
62 O
years O
; O
57 O
% O
of O
patients O
were O
men O
; O
76 O
% O
were O
White O
and O
20 O
% O
were O
Asian O
; O
48 O
% O
had O
ECOG O
PS O
0 O
. O

The O
data O
described O
in O
this O
section O
reflect O
exposure O
to O
CYRAMZA O
plus O
FOLFIRI O
in O
529 O
patients O
in O
Study O
4 O
. O

Patients O
received O
a O
median O
of O
8 O
doses O
( O
range O
1-68 O
) O
of O
CYRAMZA O
; O
the O
median O
duration O
of O
exposure O
was O
4.4 O
months O
, O
and O
169 O
( O
32 O
% O
of O
529 O
) O
patients O
received O
CYRAMZA O
for O
at O
least O
six O
months O
. O

The O
most O
common O
adverse O
reactions O
( O
all O
grades O
) O
observed O
in O
CYRAMZA O
plus O
FOLFIRI-treated O
patients O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
FOLFIRI O
were O
diarrhea B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
. O

Twenty O
percent O
of O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
received O
granulocyte O
colony-stimulating O
factors O
. O

Treatment O
discontinuation O
of O
any O
study O
drug O
due O
to O
adverse O
reactions O
occurred O
more O
frequently O
in O
CYRAMZA O
plus O
FOLFIRI-treated O
patients O
( O
29 O
% O
) O
than O
in O
placebo O
plus O
FOLFIRI-treated O
patients O
( O
13 O
% O
) O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
discontinuation O
of O
any O
component O
of O
CYRAMZA O
plus O
FOLFIRI O
as O
compared O
to O
placebo O
plus O
FOLFIRI O
, O
were O
neutropenia B-OSE_Labeled_AE
( O
12.5 O
% O
versus O
5.3 O
% O
) O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
4.2 O
% O
versus O
0.8 O
% O
) O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
treatment O
discontinuation O
of O
CYRAMZA O
were O
proteinuria B-OSE_Labeled_AE
( O
1.5 O
% O
) O
and O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
( O
1.7 O
% O
) O
. O

The O
most O
common O
serious O
adverse O
events O
with O
CYRAMZA O
plus O
FOLFIRI O
were O
diarrhea B-OSE_Labeled_AE
( O
3.6 O
% O
) O
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
( O
3.0 O
% O
) O
, O
and O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
2.8 O
% O
) O
. O

Table O
5 O
provides O
the O
frequency O
and O
severity O
of O
adverse O
reactions O
in O
Study O
4 O
. O

Table O
5 O
: O
Adverse O
Reactions O
Occurring O
at O
Incidence O
Rate O
> O
=5 O
% O
and O
a O
> O
=2 O
% O
Difference O
Between O
Arms O
in O
Patients O
Receiving O
CYRAMZA O
in O
Study O
4 O
a O
Includes O
3 O
patients O
with O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
in O
the O
CYRAMZA O
plus O
FOLFIRI O
treatment O
group O
. O

Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
CYRAMZA O
plus O
FOLFIRI O
N=529 O
Placebo O
plus O
FOLFIRI O
N=528 O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
> O
=3 O
( O
Frequency O
% O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
> O
=3 O
( O
Frequency O
% O
) O
Blood B-NonOSE_AE
and O
Lymphatic O
System O
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
59 O
38 O
46 O
23 O
Thrombocytopenia B-OSE_Labeled_AE
28 O
3 O
14 O
< O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
37 O
2 O
27 O
2 O
Diarrhea B-OSE_Labeled_AE
60 O
11 O
51 O
10 O
Gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
events O
12 O
2 O
7 O
1 O
Stomatitis B-OSE_Labeled_AE
31 O
4 O
21 O
2 O
General O
Disorders O
and O
Administration B-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
20 O
< O
1 O
9 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypoalbuminemia B-OSE_Labeled_AE
6 O
1 O
2 O
0 O
Renal B-NonOSE_AE
and O
Urinary O
Disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
a O
17 O
3 O
5 O
< O
1 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
33 O
0 O
15 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
13 O
1 O
5 O
< O
1 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
26 O
11 O
9 O
3 O
Clinically O
relevant O
adverse O
reactions O
reported O
in O
> O
=1 O
% O
and O
< O
5 O
% O
of O
CYRAMZA O
plus O
FOLFIRI-treated O
patients O
in O
Study O
4 O
consisted O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
( O
1.7 O
% O
CYRAMZA O
plus O
FOLFIRI O
versus O
0.6 O
% O
for O
placebo O
plus O
FOLFIRI O
) O
. O

Thyroid O
stimulating O
hormone O
( O
TSH O
) O
levels O
were O
evaluated O
in O
224 O
patients O
( O
115 O
CYRAMZA O
plus O
FOLFIRI-treated O
patients O
and O
109 O
placebo O
plus O
FOLFIRI-treated O
patients O
) O
with O
normal O
baseline O
TSH O
levels O
. O

Patients O
underwent O
periodic O
TSH O
laboratory O
assessments O
until O
30 O
days O
after O
the O
last O
dose O
of O
study O
treatment O
. O

Increased B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
levels O
were O
observed O
in O
53 O
( O
46 O
% O
) O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
compared O
with O
4 O
( O
4 O
% O
) O
patients O
treated O
with O
placebo O
plus O
FOLFIRI O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
the O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

In O
23 O
clinical O
trials O
, O
86/2890 O
( O
3.0 O
% O
) O
of O
CYRAMZA-treated O
patients O
tested O
positive B-OSE_Labeled_AE
for O
treatment-emergent O
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
ramucirumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
by O
an O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O

Neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected I-OSE_Labeled_AE
in O
14 O
of O
the O
86 O
patients O
who O
tested O
positive O
for O
treatment-emergent O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
ramucirumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
antibody O
) O
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
CYRAMZA I-NonOSE_AE
with O
the O
incidences O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

